Agios Pharmaceuticals (NASDAQ:AGIO) Trading Down 4.4% – What’s Next?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) dropped 4.4% during mid-day trading on Tuesday . The stock traded as low as $28.05 and last traded at $28.02. Approximately 92,307 shares traded hands during trading, a decline of 87% from the average daily volume of 699,357 shares. The stock had previously closed at $29.30.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on AGIO shares. Royal Bank of Canada raised their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Scotiabank upped their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Finally, HC Wainwright initiated coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They set a “buy” rating and a $58.00 price objective for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $56.57.

Agios Pharmaceuticals Stock Down 5.9 %

The firm has a 50 day moving average price of $33.11 and a 200 day moving average price of $40.71. The stock has a market capitalization of $1.58 billion, a PE ratio of 2.43 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, equities analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.93% of the stock is owned by insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Agios Pharmaceuticals by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock worth $185,045,000 after purchasing an additional 85,339 shares during the last quarter. State Street Corp raised its stake in shares of Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after purchasing an additional 216,484 shares during the period. Jefferies Financial Group Inc. bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth $49,290,000. Geode Capital Management LLC boosted its holdings in shares of Agios Pharmaceuticals by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock worth $60,326,000 after buying an additional 6,101 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. grew its position in Agios Pharmaceuticals by 2.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company’s stock valued at $35,152,000 after buying an additional 25,600 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.